ArticleScientific reports2020
The anti-inflammatory potential of cefazolin as common gamma chain cytokine inhibitor.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Human ex vivo comparison of Escherichia coli and Pseudomonas aeruginosa lipopolysaccharide-induced immune responses and cefiderocol effects in whole blood.Medical microbiology and immunology · 2026Article
- Peri-Operative Antimicrobial Prophylaxis Modulates CD4Antibiotics (Basel, Switzerland) · 2025Article
- Yunweiling alleviates functional constipation: integrating network pharmacology and experimental study.Animal models and experimental medicine · 2025Article
- Regulation of the innate immune response in rheumatoid arthritis.Frontiers in immunology · 2025Review
- The contribution of probiotics for the double-edge effect of cefazolin on postoperative neurocognitive disorders by rebalancing the gut microbiota.Frontiers in neuroscience · 2023Article
- Characterizing the influence of various antimicrobials used for metaphylaxis against bovine respiratory disease on host transcriptome responses.Frontiers in veterinary science · 2023Article
- Progress of Research into Novel Drugs and Potential Drug Targets against Porcine Pseudorabies Virus.Viruses · 2022Review
- Cefiderocol Protects against Cytokine- and Endotoxin-Induced Disruption of Vascular Endothelial Cell Integrity in an In Vitro Experimental Model.Antibiotics (Basel, Switzerland) · 2022Article
- Integrating heterogeneous data to facilitate COVID-19 drug repurposing.Drug discovery today · 2022Review
- Novel Therapeutic Strategies for Celiac Disease.Middle East journal of digestive diseases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A continuing quest for specific inhibitors of proinflammatory cytokines brings promise for effective therapies designed for inflammatory and autoimmune disorders. Cefazolin, a safe, first-generation cephalosporin antibiotic, has been recently shown to specifically interact with interleukin 15 (IL-15) receptor subunit α (IL-15Rα) and to inhibit IL-15-dependent TNF-α and IL-17 synthesis. The aim of this study was to elucidate cefazolin activity against IL-2, IL-4, IL-15 and IL-21, i.e. four cytokines sharing the common cytokine receptor γ chain (γ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.